



## HIV-2 Treatment in Mali and Drug Resistance Antiretroviral Profile

Aboubacar Alassane Oumar<sup>1,2,3\*</sup>, Drissa Katile<sup>4</sup>, Ibrehima Guindo<sup>5</sup>,  
Younoussa Sidibe<sup>6</sup>, Paul M. Tulkens<sup>1</sup>, Sounkalo Dao<sup>3</sup>, Jean Ruelle<sup>2</sup>  
and Benoit Mukadi-Kabamba<sup>2</sup>

<sup>1</sup>Unité de Pharmacologie Cellulaire et Moléculaire, Université Catholique de Louvain, Belgium.

<sup>2</sup>Laboratoire Référence SIDA, Université Catholique de Louvain, Belgium.

<sup>3</sup>Faculté de Médecine et d'Odontostomatologie, Bamako, Mali.

<sup>4</sup>ONG, Walé Ségou, Mali.

<sup>5</sup>Institut National de Recherche en Santé Publique, Bamako, Mali.

<sup>6</sup>Centre de Recherche Kéné Dougou Solidarité (CERKES), Sikasso, Mali.

### Authors' contributions

This work was carried out in collaboration among all authors. Authors AAO, SD and JR wrote the research protocol and organized the data collection. Authors IG, DK, YS and BMK collected the data. Author JR performed the sequences of PR and TI. Author AAO performed the sequences of the IN. Author JR analyzed the PR, TI and IN sequences. Authors SD and PMT supervised the research study. Authors JR and AAO analyzed and interpreted the results of the study. Authors AAO, SD, BMK, IG, DK and YS developed the manuscript. Authors SD, JR, BMK and PMT have revised the manuscript. All authors read and approved the final manuscript.

### Article Information

DOI: 10.9734/ISRR/2019/v8i130095

#### Editor(s):

(1) Dr. Kailash Gupta, Division of AIDS, NIAID, NIH, USA.

#### Reviewers:

(1) J. Y. Peter, University of Abuja, Nigeria.

(2) Abayomi Afe, Institute of Human Virology Nigeria, Nigeria.

Complete Peer review History: <http://www.sdiarticle3.com/review-history/50237>

Original Research Article

Received 05 May 2019  
Accepted 17 July 2019  
Published 24 July 2019

### ABSTRACT

**Aims:** We evaluated different treatment regimens administered to patients infected with HIV-2 in Mali, and studied pol polymorphisms that may influence susceptibility to antiretrovirals.

**Methodology:** We collected 57 blood samples from HIV - 2 seropositive patients in health centers in Mali (Bamako, Segou and Sikasso), including 21 treated patients and 36 untreated patients. The confirmation of the serological status and the measurement of the viral load were carried out in

\*Corresponding author: Email: [aao@icermali.org](mailto:aao@icermali.org);

Brussels. Genotypic analysis of protease, reverse transcriptase and integrase was then performed on specimens with detectable viral load. The search for ARV resistance mutations and polymorphism positions was performed in comparison with reference sequences.

**Results:** The most used treatment regimen was ZDV-3TC-LPV/ r. Genotypic analysis of protease, reverse transcriptase and integrase was performed on 20 samples from patients with detectable viral load: 16 untreated patients and 4 treated patients. Seventy-five percent of the strains analyzed correspond to group A of HIV-2. In 2cas, mutations associated with resistance to the administered molecules were found. Three viral strains from untreated patients had NRTI or PI resistance mutations. In integrase, no mutation associated with resistance was observed.

**Conclusion:** The circulation of strains carrying resistance mutations to NRTIs and PIs has been observed in Mali.

*Keywords: HIV-2; antiretroviral therapy; efficacy; mutations; Mali.*

## ABBREVIATIONS

ABC	: Abacavir
AIDS	: Acquired Immune Deficiency Syndrome
ART	: Antiretroviral Therapy
DDE	: Aspartic Acid-aspartic Acid-glutamic Acid
DNA	: DeoxyriboNucleic Acid
D4T	: Stavudine
FTC	: Emtricitabine
IDV	: Indinavir
IN	: Integrase
HIV	: Human Immunodeficiency Virus,
HIV-1	: Human Immunodeficiency Virus Type 1
HIV-2	: Human Immunodeficiency Virus Type 2
HHCC	: Histidine-histidine-cysteine-cysteine
LPV	: Lopinavir
NNRTIs	: Non-nucleoside / Nucleotide Reverse Transcriptase Inhibitors
NRTIs	: Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
PCR	: Polymerase Chain Reaction
PI	: Protease Inhibitor
PR	: Protease
UNAIDS	: United Nations Programme on HIV/ AIDS
R	: Ritonavir
RT	: Reverse Transcriptase
RT-PCR	: Reverse Transcriptase Polymerase Chain Reaction
3TC	: Lamivudine
ZDV	: Zidovudine

## 1. INTRODUCTION

HIV infection is a major public health problem in most tropical countries, particularly in sub-Saharan Africa [1]. In 2016, UNAIDS estimated nearly 36.7 million people living with HIV / AIDS worldwide, 25.8 million of them in sub-Saharan

Africa [1]. In Mali, according to the Demographic and Health Survey (DHS-V) conducted in 2012, the prevalence of HIV was estimated at 1.1% [2]. Prevalence of HIV-2 infection was 0.2% in the general population [2]. HIV-2 is endemic in West Africa and spread to India and Europe [3-5]. Compared with those infected with HIV-1, those infected with HIV-2 have a slower disease progression, lower transmission rates, and lower plasma viral loads [6]. Most HIV-2 infections occur in developing countries, where access to antiretroviral therapy (ART) is limited. HIV-2 isolates are naturally resistant to NNRTIs and fusion inhibitors [7]. There is a reduction in sensitivity for some protease inhibitors: nelfinavir, amprenavir and atazanavir with HIV-2 [8]. Few recommendations exist for the treatment of HIV-2 infection [9] and they are based on limited results. Nevertheless, some mutations appearing in the gene encoding reverse transcriptase (RT) have been clearly linked to treatment failure [10]. New studies are useful to define which mutations appear on treatment, which others are natural variations or genetic polymorphisms and whether some of these polymorphisms have an impact on ART sensitivity. In Mali, no study on HIV-2 infection has been carried out. This study aims to determine the resistance profile of HIV-2 patients before and after antiretroviral treatment in Mali.

## 2. MATERIALS AND METHODS

This is a prospective study of the genotypic profile in 21 HIV-2 patients undergoing treatment and 36 untreated patients not yet exposed to any Antiretroviral Therapy (ARV). Our sample was exhaustive, based on the progressive inclusion of HIV-2 patients received in Mali.

### 2.1 Study Population

**Case:** Patients infected with HIV-2, confirmed by 2 rapid tests, under treatment for at least 6

months, over 18 years old and signed an informed consent form.

**Control:** Patient infected with HIV-2, confirmed by 2 rapid tests, not yet exposed to any ARV and regularly monitored in health facilities, over 18 years old and signed an informed consent form.

## 2.2 Blood Sampling

Blood samples were collected in Vacutainer tubes (Becton Dickinson, San Jose, California, USA). In the 4 hours following the blood test, the plasma was separated from the cells by centrifugation at 2000 g and stored at -20°C [11]. Patient samples were taken at health centers in Bamako (National Institute for Public Health Research (INRSP), Gabriel Toure Hospital University, NGO Walé de Ségou, Kéné Dougou Solidarité Research Center (CERKES) in Sikasso). A second aliquot of biological material was stored at -20°C. These frozen samples were then sent to the AIDS Reference Laboratory of the Catholic University of Louvain (UCL) in Brussels, Belgium for an HIV-2 confirmation test, a plasma viral load and a sequencing of ARV target genes (the reverse transcriptase, protease and integrase). We had obtained the informed consent of patient before inclusion. The quantity of blood taken per patient was 6-7 ml for adults, 4-5 ml for young people. Patients younger than 18 years have not included in the study.

## 2.3 Serological Tests

The serological tests used in Mali for the HIV-2 screening were carried out according to the Malian algorithm (2 rapid tests in screening): the Genie® II HIV-1 / HIV-2 (Sanofi Diagnostics Pasteur, France) and the ImmunoComb® II HIV 1 & 2 BiSpot (Organics, Strasbourg, France). In Belgium, INNO-LIA HIV I / II Score (Innogenetics, Gent, Belgium) was used to determine HIV-1 or HIV-2 status. These tests were carried out in accordance with the operating procedures of the firms concerned.

## 2.4 Plasma Viral Load

The HIV-2 plasma viral load was quantified by real-time PCR, developed in the laboratory on a Lightcycler 2.0 platform (Roche Diagnostics, Penzberg, Germany). The assay as described by Ruelle et al. [12] was modified to obtain a sensitivity of 50 copies per ml of RNA.

## 2.5 HIV-2 Genotype

**Protease and reverse transcriptase:** The viral RNA, which had previously been extracted for the measurement of plasma viral load, was used to perform an RT-PCR reaction and a PCR, based on the protocol described by Colson et al. [13] subsequently modified to improve the detection of group B and certain variants. The PCR products were analyzed on a 2% agarose gel containing ethidium bromide: this protocol generates a fragment of 1507bp, which covers the coding regions of protease and reverse transcriptase. In this case, two PCR reactions were carried out using 2 µl of RT-PCR product. The test as described by Ruelle et al. [14], was used.

**Integrase:** An RT-PCR (nested PCR) reaction has been developed in the laboratory for the sequencing of HIV-2 integrase. This technique was described by Bercoff et al. [15]. The analysis of the sequences obtained was done using the software IDNSTM-Smartgene (Smartgene, Zug, Switzerland). The reference used for alignment is the HIV-2 ROD strain (Genbank M15390). The resistance mutations were listed according to the mutation list of ANRS version 2008 and the Rega algorithm version 8.01 (2009).

## 3. RESULTS

Fifty-seven samples from HIV-2 or dual-reactive HIV-1 and HIV-2 patients were included in this analysis: 36 from untreated patients and 21 treated patients.

The demographic and clinical characteristics of these two groups of patients are detailed in Table 1. Of the 21 patients treated, the combination of antiretroviral drugs was always based on PI, except one case of treatment of 3NRTI (ZDV + 3TC + ABC). The ZDV + 3TC + LPV / r regimen was the most used (57% of cases): 17 patients received LPV / r and 3 received IDV / r. The overall safety of the treatment was good: only four cases of adverse Drug Reaction were recorded (2 cases of peripheral neuropathies, 1 case of visual disturbance and 1 case of overweight), 2 of which required a change in the treatment regimen. Nevertheless, after average treatment duration of 23.09 months, 3 patients (14%) are in virologic failure, have a detectable plasma viral load (VL>1000). Ten patients (48%) are viral suppression (undetectable virus).

The viral genome from the patients was sequenced at the pol gene. Thirty-six patients had a detectable viral load, 25 of which had a plasma load greater than 1000copies / ml. A genotypic analysis could be carried out on the samples of 20 different patients. This analysis was completed for 14 in-between (PR + RT + IN), and partial for the others: either only integrase, or only protease and RT. The determination of the subtype or group of HIV-2 showed that 75% of the samples are in group A (15 patients) and 25% in group B (5 patients).

**Genotypic analysis of integrase:** Seventeen sequences of integrase were obtained: Among these 14 are classified in group A and 3 in group B of HIV-2.

These sequences were aligned with the reference strains ROD (M15390) and EHO (U27200), respectively representing the groups A and B of HIV-2. Of the 32 positions described in HIV-1 as being associated with integrase inhibitor resistance, 25 positions were conserved and 7 positions were variable (Table 2). No known primary resistance mutation, described in both HIV-1 and HIV-2, has been detected. The secondary resistance mutations of HIV-1 do not appear in our group of patients but variable positions at H51Q (2 cases); A153S (1 case). All the integrases have the same length for the samples of the group A, namely 293aa. This length is nevertheless variable among the samples of the group B: 287aa for one, 301aa for the two others.

**Genotypic analysis of protease and reverse transcriptase:** Sixteen sequences of protease and reverse transcriptase were obtained: of these 11 are classified in group A and 5 in group B of HIV-2. Mutations potentially implicated in resistance to protease inhibitors and reverse transcriptase inhibitors were found in 4 treated patients and 3 untreated patients. Among these, the primary mutation M184V, known to cause resistance to lamivudine and emtricitabine, was present in 2 treated patients, but also in two untreated patients (Tables 3, 4). One of the two untreated patients carrying this mutation (code 6120) is a child born to an HIV-positive mother whose mother had been treated with ARVs: the virus transmitted from mother to child was probably carrying the resistance mutations presented in the (Table 4).

The majority of mutations potentially involved in resistance have been found in the protease. Among the patients treated, we find the

association of mutations V62I, V71I, and I82F in one case, and the V71I mutation in the others (Table 3). The association of mutations may explain treatment failure in patients 6011 and 6051, but does not explain the failure of treatment in patients 6050 and 6053. In naive patients, there are other mutations described in the Table 4, mutations V47A and L90M, known to cause resistance to lopinavir, and saquinavir and other PI respectively. Patient 6126, carrying this L90M mutation, is a woman whose partner has been treated.

#### 4. DISCUSSION

We describe prospective data from 57 patients infected with HIV-2. The main demographic characteristics of our series correspond to the trends described in the literature [14,16,17]. The proportion of men and women, mean weight, and average age were comparable between treated and untreated patients [14]. Nevertheless, there are more patients whose age exceeds 40 years in the group of untreated patients. This observation can be interpreted as the highest proportion of patients who do not progress in their disease in the long term, not requiring treatment. Surprisingly, we have only one patient in stage A of the disease in our cohort: in published studies, the majority of HIV-2 patients are asymptomatic, stage A [18]. In addition, 53% of untreated patients are found to be at Stage C and likely require treatment. Patients present themselves at a health care center when they are already symptomatic. It can therefore be postulated that many HIV-2 seropositive patients are not screened in Mali.

The impact of the treatment on viral replication was studied using as a marker the plasma viral load. All treated patients received a PI-containing combination, only one patient was treated with a combination of 3 NRTIs, and he was failing. After an average of 23 months of treatment, 52% of patients (11 cases) showed a detectable viral load. Only 4 patients with virologic failure could be analyzed genotypically, and had mutations associated with resistance at the level of reverse transcriptase or protease. Most patients had a detectable but often low viral load, which was insufficient for genotypic analysis based on plasma RNA. Of the 4 patient sequences treated, 2 were consistent with the loss of sensitivity to treatment administered. In order to study the genotypes of patients who could not be sequenced, an alternative is to use proviral DNA, amplified from dried blood drops. Although some specimens are available, this provirus analysis

has not yet been performed at the time of the study. As the number of cases of adverse drug reaction recorded was relatively small (4cases, or 19% of patients), the main reason for treatment failures could be attributed to poor adherence to treatment, or possibly drug interactions in some cases. Nevertheless, we do not have systematic data on treatment adherence despite some patients reporting adverse drug Reaction.

Overall, the efficacy of the treatment is low but is comparable to that found by other authors who have used an association comprising a PI [14, 16,17,19]. The number of patients treated was relatively limited in our study, but the associations received were homogeneous: 17 patients (81%) were treated with LPV/r associated with 3TC and ZDV or d4T. These combinations correspond to the associations that showed the best results in other studies or the

efficacy of the treatment was evaluated by the plasma viral load and the number of CD4 cells [14,16,17]. Yet, globally, there is a high percentage of treatment failure. In this work, the long-term treatment efficacy was difficult to evaluate because we did not have the data corresponding to treatment durations (12, 24 or 48 weeks) but an image at some point on various treatment starts after variable durations, averaging 23 months.

The suboptimal use of the treatments favors the appearance of resistant viruses. We did not observe many mutations of resistance among the patients in therapeutic failure. We have found mutations in reverse transcriptase that have been previously described: N69S, M184V and E219D [14,20-22]. The M184V mutation, the primary mutation responsible for resistance to 3TC, and FTC, was the most common. We have seen it in two naïve patients,

**Table 1. Demographic and clinical characteristics of 57 HIV-2 patients included in the study**

<b>Characteristics</b>	<b>Patients treated (n=21)</b>	<b>Patients untreated (n=36)</b>
<b>Sex</b>		
Male	7(33%)	14(38.8%)
Female	14(67%)	22(61.2%)
<b>Mean age</b>		
< 20 year	1(5%)	3(8%)
21-29 year	1(5%)	4(11%)
30-39 year	6(28%)	9(25%)
> 40 year	13(62%)	20(56%)
<b>Mean weight</b>	57.52kg	59.58 kg
<b>Stage CDC</b>		
A	1(5%)	0
B	6(29%)	17(47%)
C	14(67%)	19(53%)
<b>CD4 median</b>		
<b>Statut serologic</b>		
HIV-2	18(86%)	33(92%)
HIV-1&2	3(14%)	3(8%)
<b>Viral load</b>		
Median	131 copies/ml [0-35450]	3315 copies/ml [0-351000]
undetectable<50 copies	10(48%)	11(31%)
50-1000copies	8(38%)	3(8%)
>1000 copies	3(14%)	22(61%)
<b>Therapeutic regimen</b>		
ABC-3TC-LPV/r	1(5%)	
ZDV-3TC-ABC	1(5%)	
D4T-3TC-IDV/r	3(14%)	
D4T-3TC-LPV/r	4(19%)	
ZDV-3TC-LPV/r	12(57%)	
<b>Adverses Drug reaction</b>		
No	17(81%)	
Yes	4(19%)	

**Table 2. Variability of HIV-2 integrase at positions related to resistance to integrase inhibitors in HIV-1**

Resistance Mutation of HIV-1 INI	HIV-2 ROD subtype A consensus	Substitution (Number)	HIV-2 EHO, subtype B consensus	Substitution (Number)
H51Y	H	Q(1)	H	Q(1)
T66I/M	T		T	
V72I	I	V(2)	V	
L74I/M/A	I		I	
E92Q	E		E	
T97A	T		T	
T112I	H		H	
F121Y	F		F	
T125K	E		D	
A128T	M		M	
E138A/K	S	T(1)	T	
G140S/A	G		G	
Y143R/C	Y		Y	
Q146K	Q		E	
S147G	S		S	
Q148H/K/R/E	Q		Q	
V151I	V		V	
S153Y/A	A	S(1)	A	
M154I	M	I(1)	M	
N155S/H	N		N	
K156N	H		H	
E157Q	H		H	
K160D	N		N	
G163R	S	D(2),N(6)	D	S(1)
V165I	I		I	
V201I	I		V	
I203M	M		M	
T206S	T		T	
S230R/N	G		G	
V249I	V		V	
R263K	R		R	
C280Y	G		S	G(2)

but one of them was a child born to a previously treated HIV-positive mother, and the other a woman whose partner was probably treated. These data show that the transmission of a virus carrying the mutation M184V is possible and that this mutation is maintained without drug pressure. However, it has been described that this mutation induces a loss of replicative capacity for the virus [23], and thus the mutated variants do not continue without treatment with 3TC or FTC. This M184V variant transmission has already been observed in other studies [24, 25]. It is not known yet which mechanism or which compensatory mutations allow a mutant M184V to persist without drug pressure. Other frequency resistance mutations such as K65R and Q151M have not been observed here. Positions involved in the functionality of reverse

transcriptase have all been conserved [24,26]. Similarly, at the protease level, the regions essential for the catalytic activity of the HIV-1 protease [27] have all been conserved in the HIV-2 strains analyzed here. At the level of mutations related to resistance to protease inhibitors, the V71I mutation was the most widespread, common to the 4 cases under treatment but also found in 3 naive patients whose viruses also showed an association of mutations involved in resistance. Regarding the known primary mutations [14,28,29], the I82F primary mutation was observed in a patient under treatment and a naive patient, the V47A mutation in a naive patient and the L90M mutation also in a untreated patient. This suggests that PI strains are circulating in Mali.

**Table 3. Treatment, genotype of 4 HIV-2 treated patients**

Patient	Sub type	Treatment ART	Duration of treatment	Resistance PR	Resistance TI	Resistance IN
6011	A	D4T-3TC-IDV/r	34 month	V62V/I, V71I, I82F	M184V	
6050	A	ZDV-3TC-ABC	32 month	V71I		
6051	B	ZDV-3TC-LPV/r	58 month	V71I	M184V	
6053	B	D4T-3TC-LPV/r	15 month	V71I		

**Table 4. Genotype of 3 naive HIV-2 patients**

Patient	Subtype	Resistance PR	Resistance TI	Resistance IN
6120	A	K45R, V47A, V62A/T, V71I, L99F	M184V	
6126	B	K45R, T56A, V71I, L90M		
6130	A	I54M, V71I, I82F, L99F	M184V	

The circulation of resistance strains, the low sensitivity towards certain protease inhibitors compared to HIV-1 [16], combined with the natural resistance to NNRTI and enfuvirtide, complicates the management of HIV-2 infection and double infections. The current need is to make available new molecules in the most affected countries that have been shown to be effective on HIV-2, such as darunavir, raltegravir and elvitegravir [30-35]. We also sequenced the region of the integrase-encoding pol gene, with all patients in this study having never been treated with integrase inhibitors. Seventeen sequences were obtained, 14 aligning with group A and 3 with group B. No primary resistance mutations to raltegravir or elvitegravir described were detected in our patient group. Among the 32 positions known to be associated with resistance in HIV-1, 25 positions were conserved and 7 positions were variable: similar results have been described in the literature [36]. These variations do not seem to influence the susceptibility of HIV-2 to integrase inhibitors [36, 37]. As the therapeutic arsenal is reduced compared to HIV-1, this new class of drugs represents a new therapeutic option for patients infected with HIV-2 or co-infected HIV-1 and 2. It seems that the regions involved in the catalytic activity are well conserved [36,38]: the positions involved at the site of the binding with zinc (HHCC), the catalytic triad DDE, and the viral DNA binding domain RKK have been preserved in 100% of our samples. Other essential positions for viral DNA binding, integration and replication of HIV-1, namely the Q62, H67, N120, N144 and Q148 positions, are also conserved at the level of HIV-2 integrase, highlighting their crucial importance for enzymatic activity.

The length of the protein seems variable in HIV-2: While the integrase makes 288 amino acids in HIV-1, its length is 293 aa for the samples of group A and varies between 287 and 301 aa for the samples of the group B analyzes. Similar results were observed in a cohort of HIV-2 patients in France [36]. The consequences of these variations are largely unknown but do not seem to affect the replicative capacity of the virus.

## 5. CONCLUSIONS

Three strains from untreated patients displayed mutations in protease and reverse transcriptase resistance, implying either that resistant viruses are circulating in Mali, or that some people are taking antiretroviral therapy without medical supervision. On the other hand, no mutation related to the resistance was observed at the level of the integrase: the integrase inhibitors could therefore represent a new therapeutic option for the HIV-2 patients in Mali.

## CONSENT AND ETHICAL APPROVAL

The study protocols were approved by the ethics committee of the Faculty of Medicine, Pharmacy and Dentistry of Bamako, the institutional Review Board (IRB) of Catholic University of Louvain under the number 09.084.

## COMPETING INTERESTS

Authors have declared that no competing interests exist.

## REFERENCES

1. UNAIDS/WHO. Global Report.UNAIDS report on the global AIDS epidemic 2016. Geneva: UNAIDS. 2016;218.
2. Samake S, Traoré SM, Ba S, Dembele E, Diop M, Mariko S. Enquête Démographique de la Santé au Mali, 2012-2013. In: CPS, ed. V. Bamako: ICF International. 2012;577.
3. Kashyap B, Gautam H, Bhalla P. Epidemiology and seroprevalence of human immunodeficiency virus type 2. *Intervirolgy*. 2011;54(3):151-5.
4. Abouya L, Coulibaly IM, Wiktor SZ, Coulibaly D, N'Kragbo M, N'Gbo A, et al. The Cote d'Ivoire national HIV counseling and testing program for tuberculosis patients: Implementation and analysis of epidemiologic data. *AIDS*. 1998;12(5): 505-12.
5. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. *Science*. 1994; 265(5178):1587-90.
6. De Cock KM, Adjorlolo G, Ekpini E, Sibailly T, Kouadio J, Maran M, et al. Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic. *JAMA*. 1993;270(17): 2083-6.
7. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: Implications for treatment and postexposure prophylaxis. *Antiviral Therapy*. 2004;9(1): 57-65.
8. Rodes B, Sheldon J, Toro C, Jimenez V, Alvarez MA, Soriano V. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. *The Journal of Anti Microbial Chemotherapy*. 2006;57(4): 709-13.
9. Gilleece Y, Chadwick DR, Breuer J, Hawkins D, Smit E, McCrae LX, et al. British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010. *HIV Medicine*. 2010; 11(10):611-9.
10. Damond F, Matheron S, Peytavin G, Campa P, Taieb A, Collin G, et al. Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen. *Antiviral Therapy*. 2004;9(4):635-6.
11. Pieniazek D, Ellenberger D, Janini LM, Ramos AC, Nkengasong J, Sassan-Morokro M, et al. Predominance of human immunodeficiency virus type 2 subtype B in Abidjan, Ivory Coast. *AIDS Res Hum Retroviruses*. 1999;15(6):603-8.
12. Ruelle J, Mukadi BK, Schutten M, Goubau P. Quantitative real-time PCR on Lightcycler for the detection of human immunodeficiency virus type 2 (HIV-2). *J Virol Methods*. 2004;117(1):67-74.
13. Colson P, Henry M, Tourres C, Lozachmeur D, Gallais H, Gastaut JA, et al. Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France. *J Clin Microbiol*. 2004;42(2):570-7.
14. Ruelle J, Roman F, Vandenbroucke AT, Lambert C, Fransen K, Echahidi F, et al. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database. *BMC Infectious Diseases*. 2008; 8:21.
15. Bercoff DP, Triqueneaux P, Lambert C, Oumar AA, Ternes AM, Dao S, et al. Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir. *Retrovirology*. 2010;7:98.
16. Adje C, Cheingsong R, Roels TH, Maurice C, Djomand G, Verbiest W, et al. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. *J Acquir Immune Defic Syndr*. 2001;26(5):501-6.
17. Jallow S, Alabi A, Sarge-Njie R, Peterson K, Whittle H, Corrah T, et al. Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. *J Clin Microbiol*. 2009;47(7):2200-8.
18. Matheron S, Pueyo S, Damond F, Simon F, Lepretre A, Campa P, et al. Factors associated with clinical progression in HIV-2 infected-patients: The French ANRS cohort. *AIDS*. 2003;17(18):2593-601.
19. Benard A, Damond F, Campa P, Peytavin G, Descamps D, Lascoux-Combes C, et al. Good response to lopinavir/ritonavir-containing antiretroviral regimens in



- antiretroviral-naive HIV-2-infected patients. *AIDS*. 2009;23(9):1171-3.
20. Rodes B, Holguin A, Soriano V, Dourana M, Mansinho K, Antunes F, et al. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. *J Clin Microbiol*. 2000;38(4):1370-4.
  21. Van der Ende ME, Guillon C, Boers PH, Ly TD, Gruters RA, Osterhaus AD, et al. Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy. *J Acquir Immune Defic Syndr*. 2000;25(1):11-8.
  22. Jallow S, Kaye S, Alabi A, Aveika A, Sarge-Njie R, Sabally S, et al. Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia. *AIDS*. 2006;20(10):1455-8.
  23. Turner D, Brenner B, Wainberg MA. Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1. *Clinical and Diagnostic Laboratory Immunology*. 2003;10(6):979-81.
  24. Ruelle J, Sanou M, Liu HF, Vandenbroucke AT, Duquenne A, Goubau P. Genetic polymorphisms and resistance mutations of HIV type 2 in antiretroviral-naive patients in Burkina Faso. *AIDS Res Hum Retroviruses*. 2007;23(8):955-64.
  25. Colson P, Henry M, Tivoli N, Gallais H, Gastaut JA, Moreau J, et al. Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France. *J Med Virol*. 2005;75(3):381-90.
  26. Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. *Journal of Molecular Biology*. 1994;243(3):369-87.
  27. Parreira R, Monteiro F, Padua E, Piedade J, Venenno T, Paixao MT, et al. Natural polymorphisms of HIV type 2 pol sequences from drug-naive individuals. *AIDS Res Hum Retroviruses*. 2006;22(11):1178-82.
  28. Gottlieb GS, Badiane NM, Hawes SE, Fortes L, Toure M, Ndour CT, et al. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: Implications for HIV-2 treatment in resource-limited West Africa. *Clin Infect Dis*. 2009;48(4):476-83.
  29. M'Barek NB, Audoly G, Raoult D, Gluschankof P. HIV-2 Protease resistance defined in yeast cells. *Retrovirology*. 2006;3:58.
  30. Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Benard A, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. *Antimicrobial Agents and Chemotherapy*. 2008;52(4):1545-8.
  31. Garrett N, Xu L, Smit E, Ferns B, El-Gadi S, Anderson J. Raltegravir treatment response in an HIV-2 infected patient: A case report. *AIDS*. 2008;22(9):1091-2.
  32. Xu L, Anderson J, Garrett N, Ferns B, Wildfire A, Cook P, et al. Dynamics of raltegravir resistance profile in an HIV type 2-infected patient. *AIDS Res Hum Retroviruses*. 2009;25(8):843-7.
  33. Peterson K, Ruelle J, Vekemans M, Siegal FP, Deayton JR, Colebunders R. The role of raltegravir in the treatment of HIV-2 infections: Evidence from a case series. *Antiviral Therapy*. 2012;17(6):1097-100.
  34. Matheron S, Descamps D, Gallien S, Besseghir A, Sellier P, Blum L, et al. First line raltegravir/emtricitabine/tenofovir combination in HIV-2 infection: Phase 2 non-comparative trial (ANRS 159 HIV-2). *Clin Infect Dis*; 2018.
  35. Zheng Y, Lambert C, Arendt V, Seguin-Devaux C. Virological and immunological outcomes of elvitegravir-based regimen in a treatment-naive HIV-2-infected patient. *AIDS*. 2014;28(15):2329-31.
  36. Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Benard A, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir *in vitro*. *The Journal of Antimicrobial Chemotherapy*. 2008;62(5):914-20.
  37. Xu L, Anderson J, Ferns B, Cook P, Wildfire A, Workman J, et al. Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients. *AIDS Res Hum Retroviruses*. 2008;24(7):1003-7.

38. Qiu X, Sokoll L, Yip P, Elliott DJ, Dua R, Mohr P, et al. Comparative evaluation of three FDA-approved HIV Ag/Ab combination tests using a genetically diverse HIV panel and diagnostic specimens. J Clin Virol. 2017; 92:62-8.

© 2019 Oumar et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Peer-review history:*  
*The peer review history for this paper can be accessed here:*  
<http://www.sdiarticle3.com/review-history/50237>